126 related articles for article (PubMed ID: 17425296)
21. SAR profiles of spirocyclic nicotinamide derived selective HDAC1/HDAC2 inhibitors (SHI-1:2).
Methot JL; Hamblett CL; Mampreian DM; Jung J; Harsch A; Szewczak AA; Dahlberg WK; Middleton RE; Hughes B; Fleming JC; Wang H; Kral AM; Ozerova N; Cruz JC; Haines B; Chenard M; Kenific CM; Secrist JP; Miller TA
Bioorg Med Chem Lett; 2008 Dec; 18(23):6104-9. PubMed ID: 18951790
[TBL] [Abstract][Full Text] [Related]
22. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current.
Trepakova ES; Dech SJ; Salata JJ
J Cardiovasc Pharmacol; 2006 Feb; 47(2):211-20. PubMed ID: 16495758
[TBL] [Abstract][Full Text] [Related]
23. A new class of potent vascular endothelial growth factor receptor tyrosine kinase inhibitors: structure-activity relationships for a series of 9-alkoxymethyl-12-(3-hydroxypropyl)indeno[2,1-a]pyrrolo[3,4-c]carbazole-5-ones and the identification of CEP-5214 and its dimethylglycine ester prodrug clinical candidate CEP-7055.
Gingrich DE; Reddy DR; Iqbal MA; Singh J; Aimone LD; Angeles TS; Albom M; Yang S; Ator MA; Meyer SL; Robinson C; Ruggeri BA; Dionne CA; Vaught JL; Mallamo JP; Hudkins RL
J Med Chem; 2003 Dec; 46(25):5375-88. PubMed ID: 14640546
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of novel class II c-Met inhibitors: 2. SAR and kinase selectivity profiles of the pyrazolone series.
Liu L; Norman MH; Lee M; Xi N; Siegmund A; Boezio AA; Booker S; Choquette D; D'Angelo ND; Germain J; Yang K; Yang Y; Zhang Y; Bellon SF; Whittington DA; Harmange JC; Dominguez C; Kim TS; Dussault I
J Med Chem; 2012 Mar; 55(5):1868-97. PubMed ID: 22320327
[TBL] [Abstract][Full Text] [Related]
25. Mallotoxin is a novel human ether-a-go-go-related gene (hERG) potassium channel activator.
Zeng H; Lozinskaya IM; Lin Z; Willette RN; Brooks DP; Xu X
J Pharmacol Exp Ther; 2006 Nov; 319(2):957-62. PubMed ID: 16928897
[TBL] [Abstract][Full Text] [Related]
26. Preclinical activity of ABT-869, a multitargeted receptor tyrosine kinase inhibitor.
Albert DH; Tapang P; Magoc TJ; Pease LJ; Reuter DR; Wei RQ; Li J; Guo J; Bousquet PF; Ghoreishi-Haack NS; Wang B; Bukofzer GT; Wang YC; Stavropoulos JA; Hartandi K; Niquette AL; Soni N; Johnson EF; McCall JO; Bouska JJ; Luo Y; Donawho CK; Dai Y; Marcotte PA; Glaser KB; Michaelides MR; Davidsen SK
Mol Cancer Ther; 2006 Apr; 5(4):995-1006. PubMed ID: 16648571
[TBL] [Abstract][Full Text] [Related]
27. Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamide.
Murineddu G; Lazzari P; Ruiu S; Sanna A; Loriga G; Manca I; Falzoi M; Dessì C; Curzu MM; Chelucci G; Pani L; Pinna GA
J Med Chem; 2006 Dec; 49(25):7502-12. PubMed ID: 17149879
[TBL] [Abstract][Full Text] [Related]
28. Evaluation of functional and binding assays in cells expressing either recombinant or endogenous hERG channel.
Murphy SM; Palmer M; Poole MF; Padegimas L; Hunady K; Danzig J; Gill S; Gill R; Ting A; Sherf B; Brunden K; Stricker-Krongrad A
J Pharmacol Toxicol Methods; 2006; 54(1):42-55. PubMed ID: 16326118
[TBL] [Abstract][Full Text] [Related]
29. 1,2,3,4-tetrahydroquinoline-based selective human neuronal nitric oxide synthase (nNOS) inhibitors: lead optimization studies resulting in the identification of N-(1-(2-(methylamino)ethyl)-1,2,3,4-tetrahydroquinolin-6-yl)thiophene-2-carboximidamide as a preclinical development candidate.
Ramnauth J; Renton P; Dove P; Annedi SC; Speed J; Silverman S; Mladenova G; Maddaford SP; Zinghini S; Rakhit S; Andrews J; Lee DK; Zhang D; Porreca F
J Med Chem; 2012 Mar; 55(6):2882-93. PubMed ID: 22335555
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of a series of naphthamides as potent, orally active vascular endothelial growth factor receptor-2 tyrosine kinase inhibitors.
Weiss MM; Harmange JC; Polverino AJ; Bauer D; Berry L; Berry V; Borg G; Bready J; Chen D; Choquette D; Coxon A; DeMelfi T; Doerr N; Estrada J; Flynn J; Graceffa RF; Harriman SP; Kaufman S; La DS; Long A; Neervannan S; Patel VF; Potashman M; Regal K; Roveto PM; Schrag ML; Starnes C; Tasker A; Teffera Y; Whittington DA; Zanon R
J Med Chem; 2008 Mar; 51(6):1668-80. PubMed ID: 18324759
[TBL] [Abstract][Full Text] [Related]
31. Synthesis and biological evaluation of 5-substituted 1,4-dihydroindeno[1,2-c]pyrazoles as multitargeted receptor tyrosine kinase inhibitors.
Akritopoulou-Zanze I; Albert DH; Bousquet PF; Cunha GA; Harris CM; Moskey M; Dinges J; Stewart KD; Sowin TJ
Bioorg Med Chem Lett; 2007 Jun; 17(11):3136-40. PubMed ID: 17391959
[TBL] [Abstract][Full Text] [Related]
32. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.
Pietras K; Hanahan D
J Clin Oncol; 2005 Feb; 23(5):939-52. PubMed ID: 15557593
[TBL] [Abstract][Full Text] [Related]
33. 2-[2-(3,4-dichloro-phenyl)-2,3-dihydro-1H-isoindol-5-ylamino]-nicotinic acid (PD-307243) causes instantaneous current through human ether-a-go-go-related gene potassium channels.
Gordon E; Lozinskaya IM; Lin Z; Semus SF; Blaney FE; Willette RN; Xu X
Mol Pharmacol; 2008 Mar; 73(3):639-51. PubMed ID: 18042732
[TBL] [Abstract][Full Text] [Related]
34. Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity.
Ali A; Thompson CF; Balkovec JM; Graham DW; Hammond ML; Quraishi N; Tata JR; Einstein M; Ge L; Harris G; Kelly TM; Mazur P; Pandit S; Santoro J; Sitlani A; Wang C; Williamson J; Miller DK; Thompson CM; Zaller DM; Forrest MJ; Carballo-Jane E; Luell S
J Med Chem; 2004 May; 47(10):2441-52. PubMed ID: 15115388
[TBL] [Abstract][Full Text] [Related]
35. Synthesis and structure-activity relationships of pyrazine-pyridine biheteroaryls as novel, potent, and selective vascular endothelial growth factor receptor-2 inhibitors.
Kuo GH; Prouty C; Wang A; Emanuel S; Deangelis A; Zhang Y; Song F; Beall L; Connolly PJ; Karnachi P; Chen X; Gruninger RH; Sechler J; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(15):4892-909. PubMed ID: 16033269
[TBL] [Abstract][Full Text] [Related]
36. SAR Investigation and Discovery of Water-Soluble 1-Methyl-1,4-dihydroindeno[1,2-
Cui YJ; Liu C; Ma CC; Ji YT; Yao YL; Tang LQ; Zhang CM; Wu JD; Liu ZP
J Med Chem; 2020 Dec; 63(23):14840-14866. PubMed ID: 33201714
[TBL] [Abstract][Full Text] [Related]
37. Thienopyridine urea inhibitors of KDR kinase.
Heyman HR; Frey RR; Bousquet PF; Cunha GA; Moskey MD; Ahmed AA; Soni NB; Marcotte PA; Pease LJ; Glaser KB; Yates M; Bouska JJ; Albert DH; Black-Schaefer CL; Dandliker PJ; Stewart KD; Rafferty P; Davidsen SK; Michaelides MR; Curtin ML
Bioorg Med Chem Lett; 2007 Mar; 17(5):1246-9. PubMed ID: 17188869
[TBL] [Abstract][Full Text] [Related]
38. Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3.
Hu-Lowe DD; Zou HY; Grazzini ML; Hallin ME; Wickman GR; Amundson K; Chen JH; Rewolinski DA; Yamazaki S; Wu EY; McTigue MA; Murray BW; Kania RS; O'Connor P; Shalinsky DR; Bender SL
Clin Cancer Res; 2008 Nov; 14(22):7272-83. PubMed ID: 19010843
[TBL] [Abstract][Full Text] [Related]
39. Biochemical characterization of TAK-593, a novel VEGFR/PDGFR inhibitor with a two-step slow binding mechanism.
Iwata H; Imamura S; Hori A; Hixon MS; Kimura H; Miki H
Biochemistry; 2011 Feb; 50(5):738-51. PubMed ID: 21182308
[TBL] [Abstract][Full Text] [Related]
40. De novo design of a picomolar nonbasic 5-HT(1B) receptor antagonist.
Nugiel DA; Krumrine JR; Hill DC; Damewood JR; Bernstein PR; Sobotka-Briner CD; Liu J; Zacco A; Pierson ME
J Med Chem; 2010 Feb; 53(4):1876-80. PubMed ID: 20088516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
